214 related articles for article (PubMed ID: 14598082)
1. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
Martinelli P; Contin M; Scaglione C; Riva R; Albani F; Baruzzi A
Neurol Sci; 2003 Oct; 24(3):192-3. PubMed ID: 14598082
[TBL] [Abstract][Full Text] [Related]
2. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.
Arabia G; Zappia M; Bosco D; Crescibene L; Bagalà A; Bastone L; Caracciolo M; Scornaienghi M; Quattrone A
Neurol Sci; 2002 Sep; 23 Suppl 2():S53-4. PubMed ID: 12548340
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
4. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
[TBL] [Abstract][Full Text] [Related]
5. [Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients].
Gómez JC; Rouco I; Velasco F; Tijero B; Garamendi I; Lezcano E; Zarranz JJ
Neurologia; 2008 Oct; 23(8):494-8. PubMed ID: 18770057
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: report of one case.
Carecchio M; Collini A; Comi C; Cantello R; Bhatia KP; Monaco F
Mov Disord; 2010 Aug; 25(11):1760-2. PubMed ID: 20645401
[No Abstract] [Full Text] [Related]
7. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
[TBL] [Abstract][Full Text] [Related]
8. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
Harder S; Baas H
Clin Pharmacol Ther; 1998 Aug; 64(2):183-91. PubMed ID: 9728899
[TBL] [Abstract][Full Text] [Related]
9. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
Zappia M; Annesi G; Nicoletti G; Arabia G; Annesi F; Messina D; Pugliese P; Spadafora P; Tarantino P; Carrideo S; Civitelli D; De Marco EV; Cirò-Candiano IC; Gambardella A; Quattrone A
Arch Neurol; 2005 Apr; 62(4):601-5. PubMed ID: 15824260
[TBL] [Abstract][Full Text] [Related]
11. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A
Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097
[TBL] [Abstract][Full Text] [Related]
12. Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease.
Müller T; Muhlack S
Parkinsonism Relat Disord; 2010 Dec; 16(10):688-9. PubMed ID: 20719554
[No Abstract] [Full Text] [Related]
13. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Dessibourg CA; Gachoud JP
Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
Hauser RA; McDermott MP; Messing S
Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
[TBL] [Abstract][Full Text] [Related]
15. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group.
Clin Neuropharmacol; 1999; 22(4):220-5. PubMed ID: 10442252
[TBL] [Abstract][Full Text] [Related]
16. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
Walker RW; Howells AR; Gray WK
Parkinsonism Relat Disord; 2011 Jan; 17(1):27-9. PubMed ID: 21051272
[TBL] [Abstract][Full Text] [Related]
17. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease.
Nagayama H; Ueda M; Kumagai T; Tsukamoto K; Nishiyama Y; Nishimura S; Hamamoto M; Katayama Y
Parkinsonism Relat Disord; 2011 Mar; 17(3):150-2. PubMed ID: 21172738
[TBL] [Abstract][Full Text] [Related]
18. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
20. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
Stocchi F; Vacca L; Ruggieri S; Olanow CW
Arch Neurol; 2005 Jun; 62(6):905-10. PubMed ID: 15956161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
